ECSP12012026A - Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas - Google Patents
Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismasInfo
- Publication number
- ECSP12012026A ECSP12012026A ECSP12012026A ECSP12012026A EC SP12012026 A ECSP12012026 A EC SP12012026A EC SP12012026 A ECSP12012026 A EC SP12012026A EC SP12012026 A ECSP12012026 A EC SP12012026A
- Authority
- EC
- Ecuador
- Prior art keywords
- phenyl
- piperazin
- urea
- amino
- methyl
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000004683 dihydrates Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente tecnología proporciona novedosas formas cristalinas anhidras e hidratadas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea, polimorfos amorfos y cristalinos anhidros de su sal de ácido monofosfórico, y la sal de clorhidrato, incluyendo su dihidrato. La presente tecnología proporciona además métodos para la preparación de las diferentes formas, composiciones que las contienen, y métodos para el tratamiento mediante el empleo de las mismas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26715509P | 2009-12-07 | 2009-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12012026A true ECSP12012026A (es) | 2012-08-31 |
Family
ID=43983750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12012026 ECSP12012026A (es) | 2009-12-07 | 2012-07-05 | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9067896B2 (es) |
| EP (1) | EP2509963B1 (es) |
| JP (2) | JP5714024B2 (es) |
| KR (1) | KR101787784B1 (es) |
| CN (5) | CN105061332A (es) |
| AR (2) | AR079257A1 (es) |
| AU (1) | AU2010328391B2 (es) |
| BR (1) | BR112012013784B1 (es) |
| CA (1) | CA2781431C (es) |
| CL (1) | CL2012001480A1 (es) |
| DK (1) | DK2509963T3 (es) |
| EC (1) | ECSP12012026A (es) |
| ES (1) | ES2562462T3 (es) |
| GT (1) | GT201200181A (es) |
| HR (1) | HRP20160126T1 (es) |
| HU (1) | HUE026983T2 (es) |
| IL (1) | IL220012B (es) |
| JO (1) | JO3061B1 (es) |
| MA (1) | MA33849B1 (es) |
| MX (1) | MX2012006562A (es) |
| MY (1) | MY158333A (es) |
| NZ (3) | NZ700778A (es) |
| PE (1) | PE20121499A1 (es) |
| PH (2) | PH12014502593A1 (es) |
| PL (1) | PL2509963T3 (es) |
| RU (1) | RU2572848C2 (es) |
| SG (1) | SG10201408063SA (es) |
| SI (1) | SI2509963T1 (es) |
| TN (1) | TN2012000263A1 (es) |
| TW (1) | TWI526440B (es) |
| WO (1) | WO2011071821A1 (es) |
| ZA (1) | ZA201203612B (es) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| AU2013241664B2 (en) | 2012-03-30 | 2016-05-19 | Novartis Ag | FGFR inhibitor for use in the treatment of hypophosphatemic disorders |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
| TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| WO2015006492A1 (en) | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| LT3057943T (lt) * | 2013-10-18 | 2018-11-12 | Eisai R&D Management Co., Ltd. | Pirimidino fgfr4 slopikliai |
| JP6522619B2 (ja) * | 2013-12-13 | 2019-05-29 | ノバルティス アーゲー | 医薬剤形 |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| BR112017002268B1 (pt) | 2014-08-18 | 2022-11-08 | Eisai R&D Management Co., Ltd | Sal de derivado de piridina monocíclica e cristal do mesmo |
| US20170304313A1 (en) | 2014-10-06 | 2017-10-26 | Novartis Ag | Therapeutic Combination For The Treatment Of Cancer |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| RU2712222C2 (ru) | 2015-03-25 | 2020-01-27 | Нэшнл Кэнсер Сентер | Терапевтическое средство против рака желчных протоков |
| US10130629B2 (en) | 2015-03-25 | 2018-11-20 | Novartis Ag | Pharmaceutical combinations |
| WO2016168331A1 (en) | 2015-04-14 | 2016-10-20 | Eisai R&D Management Co., Ltd. | Crystalline fgfr4 inhibitor compound and uses thereof |
| CN104803925B (zh) * | 2015-04-16 | 2018-01-12 | 温州医科大学 | 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途 |
| WO2016189472A1 (en) | 2015-05-28 | 2016-12-01 | Novartis Ag | Fgfr inhibitor for use in the treatment of the phosphaturic mesenchymal tumor |
| WO2017104739A1 (ja) | 2015-12-17 | 2017-06-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳がん治療剤 |
| JP7372740B2 (ja) | 2016-05-10 | 2023-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
| WO2017198221A1 (zh) * | 2016-05-20 | 2017-11-23 | 浙江海正药业股份有限公司 | 嘧啶类衍生物、其制备方法和其在医药上的用途 |
| CA3034875C (en) * | 2016-08-23 | 2024-05-28 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107176954B (zh) | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
| AU2018361264B2 (en) * | 2017-11-01 | 2021-04-01 | Guangdong Xianqiang Pharmaceutical Co., Ltd | Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof |
| BR112020017922A2 (pt) | 2018-03-28 | 2020-12-22 | Eisai R&D Management Co., Ltd. | Agente terapêutico para carcinoma hepatocelular |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| ES2991427T3 (es) | 2018-05-04 | 2024-12-03 | Incyte Corp | Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021073494A1 (en) * | 2019-10-14 | 2021-04-22 | Hutchison Medipharma Limited | The salts of a compound and the crystalline forms thereof |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20230121825A (ko) * | 2020-12-18 | 2023-08-21 | 큐이디 테라퓨틱스, 인크. | 연골무형성증을 치료하는 방법 |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11583602B2 (en) | 2021-06-23 | 2023-02-21 | Kimtron, Inc. | System and method for ultra-close proximity irradiation of rotating biomass |
| CA3244743A1 (en) * | 2022-03-18 | 2025-06-13 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | SALT OF A SIX-LINK AMINO-SUBSTITUTE NITRIC HETEROCYCLIC COMPOUND, CRYSTALLINE FORM THEREIN, CORRESPONDING PREPARATION PROCESS AND ASSOCIATED USE |
| CN115785001B (zh) * | 2022-11-23 | 2023-09-15 | 斯坦德药典标准物质研发(湖北)有限公司 | 一种英菲格拉替尼的制备方法 |
| WO2024186882A1 (en) | 2023-03-06 | 2024-09-12 | Qed Therapeutics, Inc. | Methods of treating skeletal dysplasias |
| CN120021412A (zh) * | 2023-09-18 | 2025-05-20 | 上海润石医药科技有限公司 | 包含杂芳基氧基萘类化合物的药物组合物及其制备方法和应用 |
| WO2025090870A1 (en) | 2023-10-27 | 2025-05-01 | Qed Therapeutics, Inc. | Infigratinib and metabolites thereof for use in methods of treating skeletal disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| CN101242843A (zh) * | 2005-06-10 | 2008-08-13 | 詹森药业有限公司 | 作为激酶调节剂的氨基嘧啶类化合物 |
| WO2007056593A2 (en) * | 2005-11-08 | 2007-05-18 | Choongwae Pharma Corporation | α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS |
| MEP3808A (xx) * | 2005-12-21 | 2010-02-10 | Novartis Ag | Derivati pirimidinil aril uree kao fgf inhibitori |
| JP5539963B2 (ja) * | 2008-04-29 | 2014-07-02 | ノバルティス アーゲー | 線維芽細胞増殖因子受容体のキナーゼ活性のモジュレーションをモニタリングする方法、および該方法の使用 |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
-
2010
- 2010-12-03 AR ARP100104472A patent/AR079257A1/es not_active Application Discontinuation
- 2010-12-05 JO JOP/2010/0433A patent/JO3061B1/ar active
- 2010-12-06 CN CN201510484635.8A patent/CN105061332A/zh active Pending
- 2010-12-06 PL PL10788479T patent/PL2509963T3/pl unknown
- 2010-12-06 HR HRP20160126T patent/HRP20160126T1/hr unknown
- 2010-12-06 TW TW099142438A patent/TWI526440B/zh active
- 2010-12-06 RU RU2012128351/04A patent/RU2572848C2/ru active
- 2010-12-06 SI SI201031119A patent/SI2509963T1/sl unknown
- 2010-12-06 NZ NZ700778A patent/NZ700778A/en unknown
- 2010-12-06 EP EP10788479.3A patent/EP2509963B1/en active Active
- 2010-12-06 MX MX2012006562A patent/MX2012006562A/es active IP Right Grant
- 2010-12-06 KR KR1020127017618A patent/KR101787784B1/ko active Active
- 2010-12-06 HU HUE10788479A patent/HUE026983T2/en unknown
- 2010-12-06 CA CA2781431A patent/CA2781431C/en active Active
- 2010-12-06 AU AU2010328391A patent/AU2010328391B2/en active Active
- 2010-12-06 CN CN201911278014.9A patent/CN111269186A/zh active Pending
- 2010-12-06 BR BR112012013784-0A patent/BR112012013784B1/pt active IP Right Grant
- 2010-12-06 PH PH12014502593A patent/PH12014502593A1/en unknown
- 2010-12-06 NZ NZ600070A patent/NZ600070A/en unknown
- 2010-12-06 WO PCT/US2010/059108 patent/WO2011071821A1/en not_active Ceased
- 2010-12-06 CN CN201911272657.2A patent/CN111100077A/zh active Pending
- 2010-12-06 PH PH1/2012/501146A patent/PH12012501146A1/en unknown
- 2010-12-06 ES ES10788479.3T patent/ES2562462T3/es active Active
- 2010-12-06 US US13/514,308 patent/US9067896B2/en active Active
- 2010-12-06 MY MYPI2012002222A patent/MY158333A/en unknown
- 2010-12-06 PE PE2012000772A patent/PE20121499A1/es active IP Right Grant
- 2010-12-06 CN CN2010800550783A patent/CN102639510A/zh active Pending
- 2010-12-06 SG SG10201408063SA patent/SG10201408063SA/en unknown
- 2010-12-06 DK DK10788479.3T patent/DK2509963T3/en active
- 2010-12-06 JP JP2012543183A patent/JP5714024B2/ja active Active
- 2010-12-06 NZ NZ624315A patent/NZ624315A/en unknown
- 2010-12-06 CN CN201911273119.5A patent/CN111100078A/zh active Pending
-
2012
- 2012-05-17 ZA ZA2012/03612A patent/ZA201203612B/en unknown
- 2012-05-24 IL IL220012A patent/IL220012B/en active IP Right Grant
- 2012-05-25 TN TNP2012000263A patent/TN2012000263A1/en unknown
- 2012-06-06 CL CL2012001480A patent/CL2012001480A1/es unknown
- 2012-06-07 GT GT201200181A patent/GT201200181A/es unknown
- 2012-06-26 MA MA35005A patent/MA33849B1/fr unknown
- 2012-07-05 EC ECSP12012026 patent/ECSP12012026A/es unknown
-
2015
- 2015-01-20 JP JP2015008550A patent/JP6019142B2/ja active Active
-
2019
- 2019-01-07 AR ARP190100029A patent/AR114946A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12012026A (es) | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas | |
| BR112014007193A2 (pt) | derivados de pirazoloquinolinona, preparação dos mesmos e uso terapêutico dos mesmos | |
| BR112012032244A2 (pt) | processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes | |
| MX355428B (es) | Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa. | |
| ECSP10010555A (es) | Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona | |
| BRPI0905147A8 (pt) | processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável | |
| CL2012001348A1 (es) | Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry. | |
| BR112014009866A2 (pt) | formulações de anticorpos e métodos | |
| BRPI0507312A (pt) | derivados de quinolina para uso como inibidores micobacterianos | |
| ECSP11011383A (es) | Sal de sodio de ácido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino}benzoico como inhibidor de dhodh | |
| CR20160465A (es) | Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275) | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
| DOP2009000130A (es) | Sal de potasio cristalina de analogos de lipoxina a4 | |
| MX2019009224A (es) | Diacilhidrazina cristalina y sus usos. | |
| BR112013017757A2 (pt) | derivado de oxazina cristalino e seu uso como inibidor de bace | |
| CL2008001131A1 (es) | Solucion de manoproteinas; proceso para producir dicha solucion de manoproteinas; proceso para estabilizar vino impidiendo o retardando la cristalizacion de sales de acido tartarico. | |
| CY1113279T1 (el) | Φαρμακευτικη συνθεση 271 | |
| BR112013028789A2 (pt) | processo | |
| CU20110108A7 (es) | [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos | |
| AR061299A1 (es) | Sales de succionato de 6-metoxi -8- [4- (1-(5- fluor) -quinolin -8-il-piperidin-4-il) -piperazin-1-il] -quinolina y formas cristalinas de las mismas | |
| BR112015006243A2 (pt) | agentes antibacterianos de fenicol | |
| CY1117185T1 (el) | Κρυσταλλικες μορφες της 3-(2,6-διχλωρο-3,5-διμεθοξυ-φαινυλ)-1-{6-[4-(4-αιθυλ-πιπεραζιν-1-υλ)-φαινυλαμινο]-πυριμιδιν-4-υλ}-1-μεθυλ-ουριας και αλατα αυτων | |
| BR112014013723A2 (pt) | formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico | |
| FR2936705B1 (fr) | Procede de rasage utilisant des derives de l'acide salicylique | |
| BR112014009217A2 (pt) | antibacterianos à base de fenicol |